A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2022-03-03
AEs
4
Serious
1
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-04-23 (study day 32); relationship: N
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-04-30 (study day 39); relationship: N
severe
serious
assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-28 (study day 128); relationship: not assessed; serious criteria: life-threatening
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-31 (study day 162); relationship: not assessed
Data queries
No data queries.